Última actualización 8 de julio de 2026
Key finding
Ao-PWV did not change significantly from baseline after 24 weeks of treatment with final mean of 9.65 m/s with lixisenatide and 9.96 m/s with placebo, p = 0.38.
The study evaluated the impact of lixisenatide on aortic pulse wave velocity in patients with CKD and type 2 diabetes, finding no significant changes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
The study evaluated the impact of lixisenatide on aortic pulse wave velocity in patients with CKD and type 2 diabetes, finding no significant changes.
Understanding the effects of diabetes medications on cardiovascular health is crucial, especially in patients with CKD, who are at higher risk for heart disease. The lack of significant changes in aortic pulse wave velocity and albuminuria suggests that while lixisenatide may help control blood sugar, it does not appear to improve certain cardiovascular or kidney health markers in this population.
The study may have limited generalizability due to specific population characteristics. Sample size and duration may not have been sufficient to detect subtle changes. The study did not assess long-term effects beyond 24 weeks.
Published in
Publication details and source links for this paper.
Nikolaos F, Panagiotis P, Dimitra S, et al. In people with CKD and type 2 diabetes the use of short-acting GLP-1 RA lixisenatide did not significantly influence Ao-PWV. Diabetes, Obesity & Metabolism. 2026;28(4):2953-2961. doi:10.1111/dom.70481
Ao-PWV did not change significantly from baseline after 24 weeks, p = 0.38.
No significant changes were observed in albuminuria, p = 0.09.
HbA1c decreased with lixisenatide compared to placebo.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) and Albuminuria, Change in aortic pulse wave velocity from baseline to week 24, HbA1c.
This study contributes evidence to
Primary intervention
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi)
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
3
Evidence pairs
415
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Albuminuria
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Albuminuria
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Change in aortic pulse wave velocity from baseline to week 24
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → Change in aortic pulse wave velocity from baseline to week 24
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → HbA1c
Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) → HbA1c
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Therapies and HbA1c, Insulin Therapies and Kidney Function.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring HbA1c
Measures HbA1c as a key outcome.
All studies on Insulin Therapies
Contributes to Insulin Therapies evidence base.
All studies measuring Kidney Function
Measures Kidney Function as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
1 results
3 results
3 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Insulin Therapies may improve HbA1c.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HbA1c
EvidenceScore™ Strong | EvidenceScore™ 79.0 | weak positive | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on 14 supporting studies with consistent results and a positive effect signal.
Limitations
Insulin Therapies may improve Kidney Function.
ConsistencyScore™: Results are mixed and should be interpreted cautiously.
Ranked evidence signals
Albuminuria
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is cautious because the available studies report mixed findings.
Limitations
Current evidence does not show a clear benefit of Insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) for Change in aortic pulse wave velocity from baseline to week 24.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in aortic pulse wave velocity from baseline to week 24
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
